These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 36540698)
1. Screening and identification of potential MERS-CoV papain-like protease (PLpro) inhibitors; Steady-state kinetic and Molecular dynamic studies. Ali Dahhas M; M Alkahtani H; Malik A; Almehizia AA; Bakheit AH; Akber Ansar S; AlAbdulkarim AS; S Alrasheed L; Alsenaidy MA Saudi Pharm J; 2023 Feb; 31(2):228-244. PubMed ID: 36540698 [TBL] [Abstract][Full Text] [Related]
2. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors. Kilianski A; Mielech AM; Deng X; Baker SC J Virol; 2013 Nov; 87(21):11955-62. PubMed ID: 23986593 [TBL] [Abstract][Full Text] [Related]
3. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. Lee H; Lei H; Santarsiero BD; Gatuz JL; Cao S; Rice AJ; Patel K; Szypulinski MZ; Ojeda I; Ghosh AK; Johnson ME ACS Chem Biol; 2015 Jun; 10(6):1456-65. PubMed ID: 25746232 [TBL] [Abstract][Full Text] [Related]
4. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. Yang X; Chen X; Bian G; Tu J; Xing Y; Wang Y; Chen Z J Gen Virol; 2014 Mar; 95(Pt 3):614-626. PubMed ID: 24362959 [TBL] [Abstract][Full Text] [Related]
5. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. Báez-Santos YM; Mielech AM; Deng X; Baker S; Mesecar AD J Virol; 2014 Nov; 88(21):12511-27. PubMed ID: 25142582 [TBL] [Abstract][Full Text] [Related]
6. Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro. Alaofi AL; Shahid M; Raish M; Ansari MA; Syed R; Kalam MA Molecules; 2022 Nov; 27(21):. PubMed ID: 36364379 [TBL] [Abstract][Full Text] [Related]
7. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Báez-Santos YM; St John SE; Mesecar AD Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382 [TBL] [Abstract][Full Text] [Related]
8. Structural and functional characterization of MERS coronavirus papain-like protease. Lin MH; Chuang SJ; Chen CC; Cheng SC; Cheng KW; Lin CH; Sun CY; Chou CY J Biomed Sci; 2014 Jun; 21(1):54. PubMed ID: 24898546 [TBL] [Abstract][Full Text] [Related]
9. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches. Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151 [TBL] [Abstract][Full Text] [Related]
10. Synonymous and Biased Codon Usage by MERS CoV Papain-Like and 3CL-Proteases. Kandeel M; Altaher A Biol Pharm Bull; 2017 Jul; 40(7):1086-1091. PubMed ID: 28420819 [TBL] [Abstract][Full Text] [Related]
11. In search of RdRp and Mpro inhibitors against SARS CoV-2: Molecular docking, molecular dynamic simulations and ADMET analysis. Gajjar ND; Dhameliya TM; Shah GB J Mol Struct; 2021 Sep; 1239():130488. PubMed ID: 33903778 [TBL] [Abstract][Full Text] [Related]
12. Molecular Dynamic Studies of Interferon and Innate Immunity Resistance in MERS CoV Non-Structural Protein 3. Alfuwaires M; Altaher A; Kandeel M Biol Pharm Bull; 2017; 40(3):345-351. PubMed ID: 28250277 [TBL] [Abstract][Full Text] [Related]
13. Benchmarked molecular docking integrated molecular dynamics stability analysis for prediction of SARS-CoV-2 papain-like protease inhibition by olive secoiridoids. Thangavel N; Albratty M J King Saud Univ Sci; 2023 Jan; 35(1):102402. PubMed ID: 36338939 [TBL] [Abstract][Full Text] [Related]
14. Effective inhibition of coronavirus replication by Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206 [No Abstract] [Full Text] [Related]
15. Targeting papain-like protease for broad-spectrum coronavirus inhibition. Yuan S; Gao X; Tang K; Cai JP; Hu M; Luo P; Wen L; Ye ZW; Luo C; Tsang JO; Chan CC; Huang Y; Cao J; Liang R; Qin Z; Qin B; Yin F; Chu H; Jin DY; Sun R; Chan JF; Cui S; Yuen KY Protein Cell; 2022 Dec; 13(12):940-953. PubMed ID: 35384604 [TBL] [Abstract][Full Text] [Related]
16. Utilizing sinapic acid as an inhibitory antiviral agent against MERS-CoV PLpro. Shahid M; Alaofi AL; Ahmad Ansari M; Fayaz Ahmad S; Alsuwayeh S; Taha E; Raish M Saudi Pharm J; 2024 Apr; 32(4):101986. PubMed ID: 38487020 [TBL] [Abstract][Full Text] [Related]
17. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study. Rahul S; Sarkar A J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069 [TBL] [Abstract][Full Text] [Related]
18. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery. Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510 [TBL] [Abstract][Full Text] [Related]
19. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some Amin SA; Ghosh K; Gayen S; Jha T J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618 [TBL] [Abstract][Full Text] [Related]
20. Screening of potential drug from Azadirachta Indica (Neem) extracts for SARS-CoV-2: An insight from molecular docking and MD-simulation studies. Baildya N; Khan AA; Ghosh NN; Dutta T; Chattopadhyay AP J Mol Struct; 2021 Mar; 1227():129390. PubMed ID: 33041371 [No Abstract] [Full Text] [Related] [Next] [New Search]